Literature DB >> 20447493

Treatment of skin cancers in epidermolysis bullosa.

Supriya S Venugopal1, Dédée F Murrell.   

Abstract

Squamous cell carcinomas (SCCs) are highly aggressive in patients with epidermolysis bullosa (EB). Non-ultraviolet-related SCCs are the leading cause of death in patients with recessive dystrophic EB, particularly recessive dystrophic EB-generalized severe subtype (RDEB-GS). The mechanism of SCC development in patients with RDEB continues to be investigated and several theories have been reported in the literature. Copyright 2010. Published by Elsevier Inc.

Entities:  

Mesh：

Year:  2010        PMID： 20447493     DOI： 10.1016/j.det.2010.01.009

Source DB:  PubMed          Journal:  Dermatol Clin        ISSN： 0733-8635            Impact factor:   3.478


  11 in total

1.  A consensus approach to wound care in epidermolysis bullosa.

Authors:  Elena Pope; Irene Lara-Corrales; Jemima Mellerio; Anna Martinez; Gregory Schultz; Robert Burrell; Laurie Goodman; Patricia Coutts; John Wagner; Upton Allen; Gary Sibbald
Journal:  J Am Acad Dermatol       Date:  2012-03-02       Impact factor: 11.527

2.  Polymeric Nanoparticles to Combat Squamous Cell Carcinomas in Patients with Dystrophic Epidermolysis Bullosa.

Authors:  Martin A C Manoukian; Susanne V Ott; Jayakumar Rajadas; Mohammed Inayathullah
Journal:  Recent Pat Nanomed       Date:  2014

3.  Access to wound dressings for patients living with epidermolysis bullosa - an Australian perspective.

Authors:  Louise J Stevens
Journal:  Int Wound J       Date:  2012-11-22       Impact factor: 3.315

Review 4.  Raising Awareness Among Healthcare Providers about Epidermolysis Bullosa and Advancing Toward a Cure.

Authors:  Aaron Tabor; Joseph V Pergolizzi; Guy Marti; John Harmon; Bernard Cohen; Jo Ann Lequang
Journal:  J Clin Aesthet Dermatol       Date:  2017-05-01

5.  Targeting the spliceosome for cutaneous squamous cell carcinoma therapy: a role for c-MYC and wild-type p53 in determining the degree of tumour selectivity.

Authors:  Lydia A Hepburn; Angela McHugh; Kenneth Fernandes; Garry Boag; Charlotte M Proby; Irene M Leigh; Mark K Saville
Journal:  Oncotarget       Date:  2018-05-01

6.  Subcutaneous spreading squamous cell carcinoma in a patient with epidermolysis bullosa.

Authors:  X Ye; S Warrier; K J Nejad; A D Parasyn
Journal:  J Surg Case Rep       Date:  2012-08-01

7.  Inherited epidermolysis bullosa: clinical and therapeutic aspects.

Authors:  Vanessa Lys Simas Yamakawa Boeira; Erica Sales Souza; Bruno de Oliveira Rocha; Pedro Dantas Oliveira; Maria de Fátima Santos Paim de Oliveira; Vitória Regina Pedreira de Almeida Rêgo; Ivonise Follador
Journal:  An Bras Dermatol       Date:  2013 Mar-Apr       Impact factor: 1.896

Review 8.  Multicentre consensus recommendations for skin care in inherited epidermolysis bullosa.

Authors:  May El Hachem; Giovanna Zambruno; Eva Bourdon-Lanoy; Annalisa Ciasulli; Christiane Buisson; Smail Hadj-Rabia; Andrea Diociaiuti; Carolina F Gouveia; Angela Hernández-Martín; Raul de Lucas Laguna; Mateja Dolenc-Voljč; Gianluca Tadini; Guglielmo Salvatori; Cristiana De Ranieri; Stephanie Leclerc-Mercier; Christine Bodemer
Journal:  Orphanet J Rare Dis       Date:  2014-05-20       Impact factor: 4.123

9.  Whole-transcriptome gene expression profiling in an epidermolysis bullosa simplex Dowling-Meara model keratinocyte cell line uncovered novel, potential therapeutic targets and affected pathways.

Authors:  Julia Herzog; Raphaela Rid; Martin Wagner; Harald Hundsberger; Andreas Eger; Johann Bauer; Kamil Önder
Journal:  BMC Res Notes       Date:  2015-12-15

10.  Preclinical comparison of proteasome and ubiquitin E1 enzyme inhibitors in cutaneous squamous cell carcinoma: the identification of mechanisms of differential sensitivity.

Authors:  Angela McHugh; Kenneth Fernandes; Andrew P South; Jemima E Mellerio; Julio C Salas-Alanís; Charlotte M Proby; Irene M Leigh; Mark K Saville
Journal:  Oncotarget       Date:  2018-04-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.